Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin
Crossref DOI link: https://doi.org/10.1007/s11095-018-2387-4
Published Online: 2018-03-21
Published Print: 2018-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hsu, Li-feng
Text and Data Mining valid from 2018-03-21
Article History
Received: 8 January 2018
Accepted: 12 March 2018
First Online: 21 March 2018